Visiox Pharma Funding Round

8/3/2022

Venture Equity

$7,000,000

Seed

The company intends to use the funds to finalize and submit the NDAs for its lead assets, manufacture initial inventory, and add key talent as the company expands its commercial team.

Private & Independent

Biopharmaceutical

303 S Broadway 125
Tarrytown, NY 10591
USA

Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. Each day is an opportunity for us to disrupt and revolutionize the current market to maximize patient and physician satisfaction. As an agile business partner, we will achieve this through a high level of collaboration with all eye care professionals. Our first asset, PDP-716, is a once-daily brimonidine for ocular hypertension and open angle glaucoma. Our second asset, SDN-037, is a twice daily topical difluprednate for post-surgical inflammation and pain. Each product utilizes a unique, proprietary, extended release technology that is patent protected through at least 2036.